Thiophen-2-ylsulfonyl indole-3-carbaldehyde thiosemicarbazones as selective prostate cancer agents: biological profiling and molecular targeting studies
Abstract
A series of thiophen-2-ylsulfonyl indole-3-carbaldehyde thiosemicarbazone derivatives 5a–5t was synthesized and evaluated for anticancer activity using biological and computational methods. The cytotoxic activity of these compounds was tested on A549, LNCaP, and HUVEC cell lines utilizing the MTT assay, with sorafenib used as a control drug. The activity of the derivatives was shown to be cell line- and substituent-dependent, with the highest cytotoxicity against LNCaP cells. Compound 5d, bearing a 2,3-dichlorophenyl group, was the most potent derivative against LNCaP cells (IC50 = 2.50 µM; SI = 33.7), while compounds 5b and 5c also showed notable activity (IC50 = 7.96 and 5.30 µM, respectively). These synthesized compounds showed preferential activity towards prostate cancer (LNCaP) cells specifically in comparison with lung cancer A549 cells. Thus, subsequent computational studies were directed to the molecular targets associated with prostate cancer. The docking study of compounds 5b–5d against AR, EGFR, VEGFR-2, AKT1, mTOR, and PI3Kα, followed by MM-GBSA analysis, indicated their good binding activity with particular reference to the AR target. An MD simulation of 250 ns on the AR-compound 5d complex confirmed the stability and constant interaction with important residues. ADME and DFT analyses determined the properties of the selected compounds. Overall, compound 5d emerged as a promising lead for further investigation against prostate cancer. Our data provide a foundation for the rational design and optimization of thiosemicarbazone-based anticancer agents and advance research into their molecular mechanisms, target selectivity, and preclinical therapeutic potential.